Top Ten Equity Holdings and Exposures

Summary by AI ^BETAClose X

Polar Capital Global Healthcare Trust plc has released its top ten equity holdings and sector and geographic exposure as of January 30, 2026. The top ten holdings, representing 44.9% of the portfolio, are led by Eli Lilly & Co at 7.4%, followed by Roche at 5.9% and AstraZeneca at 5.1%. Sector exposure is heavily weighted towards Pharmaceuticals (43.4%) and Biotechnology (19.3%), with a significant geographic concentration in the United States (44.4%) and Denmark (10.0%).

Disclaimer*

Polar Capital Global Health Tst PLC

03 February 2026

3^rd February 2026

Polar Capital Global Healthcare Trust plc (the "Company")

Top Ten Equity Holdings and Sector and Geographic Exposure as at 30^th January 2026.

Polar Capital Global Healthcare Trust plc is pleased to announce that as at 30th January 2026 the top ten equity holdings and the sector and geographic breakdown were as follows:

Top 10 Holdings	%
Eli Lilly & Co	7.4%
Roche	5.9%
AstraZeneca	5.1%
Thermo Fisher Scientific	4.4%
Novo Nordisk A/S	4.3%
Teva Pharmaceutical Industries	4.1%
Chugai Pharmaceutical Co	3.8%
UCB	3.5%
CVS Health Corp	3.4%
Argenx	3.2%
Total	44.9%

Sector Exposure	%
Pharmaceuticals	43.4%
Biotechnology	19.3%
Healthcare Services	12.3%
Life Sciences Tools & Services	11.1%
Healthcare Equipment	5.7%
Healthcare Supplies	2.6%
Managed Healthcare	2.2%
Healthcare Distributors	1.3%
Healthcare Technology	0.9%
Healthcare Facilities	0.0%
Cash	1.2%
Total	100.0%

Geographic Exposure	%
United States	44.4%
Denmark	10.0%
United Kingdom	7.6%
Germany	7.4%
Switzerland	5.9%
Japan	4.6%
Israel	4.1%
Belgium	3.5%
Ireland	3.4%
Netherlands	3.2%
India	2.1%
Sweden	1.6%
France	0.9%
Cash	1.2%
Total	100.0%

The monthly factsheet will usually be available on the Company's website on the 10^th working day after the month end and includes a commentary by the investment manager. www.Polarcapitalhealthcaretrust.com

Neither the contents of the Company's website nor the contents of any website accessible from the hyperlinks on the Company's website (or any other website) is incorporated into or forms part of this announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END